听力损失与心血管疾病之间的关联:一项Meta分析
该Meta分析纳入4项队列研究(N=940,771)和6项横断面研究(N=680,349),评估听力损失与卒中、冠心病及任何心血管疾病的关联。结果显示听力损失与卒中(OR=1.26,95%CI 1.16-1.37)、冠心病(OR=1.36,95%CI 1.13-1.64)及任何心血管疾病(OR=1.38,95%CI 1.07-1.77)均呈强关联。作者认为听力损失与心血管疾病密切相关,诊治听力损失患者的医生应知晓这一关联。
要点
- 听力损失与卒中、冠心病及任何心血管疾病均呈强关联。
- 听力损失与卒中的汇总OR为1.26(95%CI 1.16-1.37,I²=78%)。
- 听力损失与冠心病的汇总OR为1.36(95%CI 1.13-1.64,I²=96%)。
核心结论
- 研究结果表明听力损失与心血管疾病密切相关。
- 作者认为,诊治听力损失患者的医生应知晓这一关联,并从整体健康和衰老的 broader 背景看待听力损失。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和SCOPUS从建库至2022年4月27日的文献。
- 纳入4项队列研究(N=940,771)和6项横断面研究(N=680,349)。
- 由三名盲法评价者筛选报告听力损失患者卒中、冠心病及任何心血管疾病的观察性研究,并与无听力损失个体比较。
- 使用Newcastle-Ottawa量表评估研究偏倚,遵循PRISMA指南和PROSPERO注册方案(CRD42022348648)。
- 采用随机效应逆方差Meta分析合并听力损失与卒中、冠心病及任何心血管疾病关联的比值比(OR)。
主要发现
- 听力损失与卒中的汇总OR为1.26(95%CI 1.16-1.37,I²=78%)。
- 低频听力损失与卒中的汇总OR为1.33(95%CI 1.12-1.58),高频听力损失与卒中的汇总OR为1.29(95%CI 1.14-1.45)。
- 听力损失与冠心病的汇总OR为1.36(95%CI 1.13-1.64,I²=96%)。
- 听力损失与任何心血管疾病的汇总OR为1.38(95%CI 1.07-1.77,I²=99%)。
- 观察到极小发表偏倚,剪补法后汇总效应量变化极小。
关键数值与推荐
- 听力损失与卒中关联的汇总OR=1.26(95%CI 1.16-1.37,I²=78%)。
- 低频听力损失与卒中关联的汇总OR=1.33(95%CI 1.12-1.58)。
- 高频听力损失与卒中关联的汇总OR=1.29(95%CI 1.14-1.45)。
- 听力损失与冠心病关联的汇总OR=1.36(95%CI 1.13-1.64,I²=96%)。
- 听力损失与任何心血管疾病关联的汇总OR=1.38(95%CI 1.07-1.77,I²=99%)。
临床怎么用
- 作者认为,诊治听力损失患者的医生应知晓听力损失与心血管疾病的关联,并从整体健康和衰老的 broader 背景看待听力损失。
局限性
- 听力损失与卒中关联的汇总分析异质性I²=78%。
- 听力损失与冠心病关联的汇总分析异质性I²=96%。
- 听力损失与任何心血管疾病关联的汇总分析异质性I²=99%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hearing loss (HL) has been postulated to be linked to cardiovascular diseases (CVDs) via vascular mechanisms, but epidemiological associations remain unclear. The study aims to clarify the association between HL and stroke, coronary artery disease (CAD), and any CVD. DATA SOURCES: PubMed, Embase, and SCOPUS from inception until April 27, 2022. REVIEW METHODS: Three blinded reviewers selected observational studies reporting stroke, CAD, and any CVD in patients with HL, compared to individuals without HL. We extracted data, evaluated study bias using the Newcastle-Ottawa scale, following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and a PROSPERO-registered protocol (CRD42022348648). We used random-effects inverse variance meta-analyses to pool the odds ratios (ORs) for the association of HL with stroke, CAD, and any CVD. RESULTS: We included 4 cohort studies (N = 940,771) and 6 cross-sectional studies (N = 680,349). Stroke, CAD, and any CVD were all strongly associated with HL. The overall pooled OR of the association between HL and stroke was 1.26 (95% confidence interval [CI] = 1.16-1.37, I2 = 78%), and was 1.33 (95% CI = 1.12-1.58) and 1.29 (95% CI = 1.14-1.45) for low- and high-frequency HL, respectively. Minimal publication bias was observed, with minimal change to pooled effect size following trim and fill. Similarly, the pooled OR of the association between HL and CAD was 1.36 (95% CI = 1.13-1.64, I2 = 96%), while that between HL and any CVD was 1.38 (95% CI = 1.07-1.77, I2 = 99%). CONCLUSION: Our findings suggest that HL and CVD are closely related. Physicians treating patients with HL should be cognizant of this association and view HL in the broader context of general health and aging.
引用
- Tan CJ, Koh JWT, Tan BKJ, et al. Association Between Hearing Loss and Cardiovascular Disease: A Meta-analysis. Otolaryngol Head Neck Surg. 2023. PMID: 38063267. doi:10.1002/ohn.599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。